Patents by Inventor Harsh PRATAP

Harsh PRATAP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOMODULATORY TRISPECIFIC T CELL ENGAGER FUSION PROTEINS
    Publication number: 20250019440
    Abstract: The present disclosure provides fusion proteins with a multifunctional biologic design for programmed target engagement. In certain embodiments, the fusion proteins described herein provide for concurrent T cell and target antigen engagement and immune checkpoint targeting.
    Type: Application
    Filed: July 24, 2024
    Publication date: January 16, 2025
    Inventors: Surjit Bhimarao Dixit, Eric ESCOBAR-CABRERA, Florian Heinkel, Anna Von Rossum, Harsh Pratap, Maya Poffenberger, Chayne L. Piscitelli, Meghan Marie Verstraete
  • MULTIVALENT AND BISPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF
    Publication number: 20240327516
    Abstract: The present disclosure relates to multivalent, e.g., trivalent, and bispecific antibody constructs capable of binding an antigen on a cytotoxic effector cell and a tumor-associated antigen (TAA) on a tumor cell. Pharmaceutical compositions comprising such antibody constructs and methods of preparing and using such constructs and compositions, e.g., for the treatment of cancer, are also disclosed.
    Type: Application
    Filed: June 18, 2024
    Publication date: October 3, 2024
    Inventors: Nicole AFACAN, Chayne L. PISCITELLI, Thomas SPRETER VON KREUDENSTEIN, Patricia ZWIERZCHOWSKI, Nina E. WEISSER, David DOUDA, Kara WHITE-MOYES, Harsh PRATAP
  • ANTIBODY CONSTRUCTS BINDING 4-1BB AND FOLATE RECEPTOR ALPHA AND USES THEREOF
    Publication number: 20230265202
    Abstract: Described herein are antibody constructs comprising a 4- 1BB binding domain and an anti-Folate Receptor a (FRa) antigen- binding domain, wherein the 4-1BB-binding domain and the FR? antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function. The antibody constructs are used in the treatment of a subject having cancer.
    Type: Application
    Filed: April 9, 2021
    Publication date: August 24, 2023
    Inventors: Daniel T. PATTON, Lee FREIBURGER, Thomas SPRETER VON KREUDENSTEIN, David M. MILLS, Gesa VOLKERS, Dunja UROSEV, Zhuang DUAN, Elizabeth HALVORSEN, Harsh PRATAP, Brandon CLAVETTE, Anna VON ROSSUM, Patricia ZWIERZCHOWSKI, Peter Wing Yiu CHAN, Danny CHUI, Sylwia JANCOWSKI, Sukhbir Singh KANG, Grant Raymond Wickman
  • ANTIBODY CONSTRUCTS BINDING 4-1BB AND TUMOR-ASSOCIATED ANTIGENS AND USES THEREOF
    Publication number: 20230052369
    Abstract: Described herein are antibody constructs comprising a 41-1BB binding domain and an antigen-binding domain that binds to a tumor-associated antigen (TAA), wherein the 4-1BB-binding domain and the TAA antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function.
    Type: Application
    Filed: April 9, 2021
    Publication date: February 16, 2023
    Inventors: Daniel T. PATTON, David M. MILLS, Thomas SPRETER VON KREUDENSTEIN, Gesa VOLKERS, Dunja UROSEV, Lee FREIBURGER, Zhuang DUAN, Elizabeth HALVORSEN, Harsh PRATAP, Brandon CLAVETTE, Anna VON ROSSUM, Duncan BROWMAN, Peter Wing Yiu CHAN, Danny CHUI, Robert William GENE, Sylwia JANCOWSKI, Sukhbir Singh KANG, Patricia ZWIERZCHOWSKI